Associated Papers
Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.
Henderson GJ et al.
Antimicrobial Agents and Chemotherapy, 2012
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S et al.
Journal of Medical Virology, 2008
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V et al.
Antimicrobial Agents and Chemotherapy, 2005
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
Croteau G et al.
Journal of Virology, 1997
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
Doyon L et al.
Journal of Virology, 1996
Select a paper to view details